ClinicalTrials.gg
RecruitingNCT06922344Updated Apr 10, 2025

Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor

A Phase 4 interventional study of Fluconazole and Itraconazole in Pityriasis Versicolor, sponsored by Khyber Teaching Hospital. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by Khyber Teaching Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study compares the efficacy of two drugs, namely flucanazole and itraconazole for the treatment of a common fungal infection of skin.

Read the detailed description

Pityriasis versicolor is a common fungal infection of the superficial skin layers. Avalible treatment options include topical and systemic drugs. fluconazole and itraconazole are commonly used systemic agents. The aim of this study is to compare the efficacy of the two systemic drugs.

02

Conditions studied

  • Pityriasis Versicolor

Keywords

  • Pityriasis Versicolor
  • Fluconazole
  • Itraconazole
03

In context

Lead sponsor

Khyber Teaching Hospital is the lead sponsor of 29 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All cases of Pityriasis versicolor

Exclusion criteria

Exclusion Criteria:

  • Patients with history of chronic renal or liver disease, , or undergoing any kind of chemotherapy or radiotherapy or having cardiac conduction abnormalities.
  • Patients who received any anti-fungal therapy in the last one month.
  • Pregnant or lactating women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    Group A, Fluconazole group

    Group A consists of patients in whom oral fluconazole is given in dose of 300mg once weekly for 2 weeks.

    Drug: Fluconazole

  • Experimental
    Group B, Itraconazole group

    Group B consists of patients in whom oral Itraconazole is given in dose of 100mg Twice for 5 days.

    Drug: Itraconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of Treatment

    Efficacy of treatment is defined by absence of scaling by naked eye examination ,absence of yellow or golden scale reflection on woods lamp examination and absence of fungal hyphae on microscopic examination.

    Time frame: Upto 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Patient's confidentiality may be breached.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2025, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 10, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06922344
Lead sponsor
Khyber Teaching Hospital
Responsible party
Hajira Amin (Doctor, Khyber Teaching Hospital) — Principal investigator
First posted
Apr 10, 2025
Start date
Mar 1, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 10, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluconazole · Itraconazole

Start the discussion